e-learning
resources
Stockholm 2007
Monday 17.09.2007
New treatments for asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treatment of moderate-severe asthma with omalizumab is associated with a decrease in peripheral blood eosinophils
R. Zeldin, M. Massanari, M. Blogg, P. Jimenez, G. Geba (East Hanover, NJ, United States Of America; Horsham, West Sussex, United Kingdom)
Source:
Annual Congress 2007 - New treatments for asthma
Session:
New treatments for asthma
Session type:
Thematic Poster Session
Number:
2132
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Zeldin, M. Massanari, M. Blogg, P. Jimenez, G. Geba (East Hanover, NJ, United States Of America; Horsham, West Sussex, United Kingdom). Treatment of moderate-severe asthma with omalizumab is associated with a decrease in peripheral blood eosinophils. Eur Respir J 2007; 30: Suppl. 51, 2132
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study
Source: Eur Respir J, 51 (5) 1702523; 10.1183/13993003.02523-2017
Year: 2018
FE
NO
and blood eosinophil count as surrogate barkers of eosinophilic airway inflammation in patients with severe asthma
Source: Annual Congress 2010 - Induced sputum in relation: a fresh look on phenotyping and monitoring
Year: 2010
Increase in systemic IL-5 is associated with mepolizumab treatment failure in patients with severe asthma
Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Year: 2018
Mast cells are associated with exacerbations and eosinophilia in children with severe asthma
Source: Eur Respir J 2016; 48: 1320-1328
Year: 2016
Association between blood eosinophil count and exacerbation risk in patients with asthma receiving medium- or high-dosage inhaled corticosteroids
Source: International Congress 2017 – Biomarker-based asthma control
Year: 2017
In vitro responses of peripheral blood mononuclear cells in severe asthma patient treated with Mepolizumab
Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies
Year: 2020
Mepolizumab does not alter blood basophil count in severe asthma
Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses
Year: 2019
Associations of blood cytokines and eosinophils in severe asthma
Source: International Congress 2017 – Clinical points to ponder in asthma
Year: 2017
Stability of blood eosinophils over time in patients with asthma
Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations
Year: 2021
T-regulatory cells blood content in patients with asthma exacerbation
Source: Annual Congress 2011 - T-cell subsets
Year: 2011
Clinical analysis of acute exacerbation of COPD cases with increased eosinophilic granulocytes in peripheral blood
Source: International Congress 2019 – Airway disease-associated exacerbations
Year: 2019
Peripheral neutrophil stiffness is increased in COPD severe exacerbations
Source: Annual Congress 2012 - COPD monitoring in stable disease and during exacerbation
Year: 2012
Treatment of COPD exacerbations is able to influence the mononuclear cells level of the peripheral blood
Source: Annual Congress 2008 - Basic science in asthma and COPD II
Year: 2008
Standard therapy increases the sensitivity of peripheral blood lymphocytes to glucocorticoids in cystic fibrosis but not in severe asthma
Source: Annual Congress 2011 - Experimental modulation of airway inflammation
Year: 2011
Airway eosinophilia is not related to clinical and functional findings in a large group of severe refractory asthmatics
Source: Annual Congress 2006 - Monitoring airway inflammation – exhaled markers
vs
induced sputum
Year: 2006
Late Breaking Abstract - Benralizumab treatment strongly reduces blood basophils in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Late Breaking Abstract - The blood eosinophils count as a predictor of the response for omalizumab (OMA) in patients suffering from severe allergic asthma
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Heterogeneous response of airway eosinophilia to biologics in severe asthma patients
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
Sputum analysis reveals eosinophilic inflammation in difficult-to-control asthma patients with low blood eosinophils and FENO.
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept